Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Consequences for preoperative pain and function when postponing elective knee and hip arthroplasty

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Drug use in patients with short bowel syndrome and intestinal failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk factors for fatigue and impaired function eight months after hospital admission with COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Successful treatment of Clostridioidesdifficile infection with single-donorfaecal microbiota transplantation capsules

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Translation and linguistic validation of the Composite Autonomic Symptom Score COMPASS 31 in Danish

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Knowledge of the seroprevalence and duration of antibodies against SARS-CoV-2 was needed in the early phases of the COVID-19 pandemic and is still necessary for policy makers and healthcare professionals. This information allows us to better understand the risk of reinfection in previously infected individuals.

METHODS: We investigated the prevalence and duration of detectable antibodies against SARS-CoV-2 in sequentially collected samples from 379 healthcare professionals.

RESULTS: SARS-CoV-2 seroprevalence at inclusion was 5.3% (95% confidence interval (CI): 3.3-8.0%) and 25% of seropositive participants reverted during follow-up. At the end of follow-up, the calculated probability of having detectable antibodies among former seropositive participants was 72.2% (95% CI: 54.2-96.2%).

CONCLUSION: Antibodies against SARS-CoV-2 were detectable in a subset of infected individuals for a minimum of 39 weeks.

FUNDING: The assays performed at Rigshospitalet were developed with financial support from the Carlsberg Foundation (CF20-0045) and the Novo Nordisk Foundation (NFF205A0063505 and NNF20SA0064201).

TRIAL REGISTRATION: The study was registered with the Danish National Committee on Health Research Ethics (H-20022312).

OriginalsprogEngelsk
ArtikelnummerA11210843
TidsskriftDanish Medical Journal
Vol/bind69
Udgave nummer5
ISSN1603-9629
StatusUdgivet - 7 apr. 2022

Bibliografisk note

Articles published in the DMJ are “open access”. This means that the articles are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

ID: 77626405